Cambridge Nutritional Sciences (FRA:RVKA) Total Equity: €12.73 Mil (As of Sep. 2025)


What is Cambridge Nutritional Sciences Total Equity?

Cambridge Nutritional Sciences FRA:RVKA Total Equity is €12.73 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

Cambridge Nutritional Sciences's total equity for the quarter that ended in Sep. 2025 was €12.73 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cambridge Nutritional Sciences Total Equity Historical Data

* Premium members only.

The historical data trend for Cambridge Nutritional Sciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambridge Nutritional Sciences Total Equity Chart

Cambridge Nutritional Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.24 14.14 11.28 11.32 13.64

Cambridge Nutritional Sciences Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.78 11.32 11.37 13.64 12.73

Cambridge Nutritional Sciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cambridge Nutritional Sciences's Total Equity for the fiscal year that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=16.313-2.678
=13.64

Cambridge Nutritional Sciences's Total Equity for the quarter that ended in Sep. 2025 is calculated as

Total Equity=Total Assets(Q: Sep. 2025 )-Total Liabilities(Q: Sep. 2025 )
=14.611-1.882
=12.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €12.73 Mil mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a Total Equity of €12.73 Mil as of Sep. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Cambridge Nutritional Sciences and its competitors.
Is Cambridge Nutritional Sciences' Total Equity too high?
Cambridge Nutritional Sciences' current Total Equity is €12.73 Mil.
How does Cambridge Nutritional Sciences' Total Equity compare to ISRG and BDX?
Cambridge Nutritional Sciences' Total Equity of €12.73 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Cambridge Nutritional Sciences and its competitors. Cambridge Nutritional Sciences's current Total Equity is €12.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Cambridge Nutritional Sciences (FRA:RVKA) has a current Total Equity of €12.73 Mil. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 32.5% below its estimated fair value. The current Total Equity is €12.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current Total Equity is €12.73 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambridge Nutritional Sciences Business Description

Other Exchanges CNSL:UK
Address One Fleet Place, London, GBR, EC4M 7WS
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.